Natera Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Natera han disminuido a una tasa media anual de -32%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 30% al año.

Información clave

-32.0%

Tasa de crecimiento de los beneficios

-22.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	30.0%
Rentabilidad financiera	-56.8%
Margen neto	-40.2%
Próxima actualización de resultados	09 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Aug 07

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18

Natera: Cracks In The Bearish Trade

Oct 10

Natera gains after publication of data on transplant rejection assessment test

Oct 04

Natera (NASDAQ:NTRA) Has Debt But No Earnings; Should You Worry?

Sep 13

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Natera. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:NTRA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	1,083	-435	618	321
30 Sep 23	989	-499	601	326
30 Jun 23	931	-512	594	314
31 Mar 23	868	-546	591	318
31 Dec 22	820	-548	589	316
30 Sep 22	776	-546	592	300
30 Jun 22	723	-576	572	333
31 Mar 22	667	-546	550	304
31 Dec 21	625	-472	511	264
30 Sep 21	565	-408	453	231
30 Jun 21	505	-315	402	157
31 Mar 21	449	-258	346	122
31 Dec 20	391	-230	304	100
30 Sep 20	362	-189	272	77
30 Jun 20	342	-153	251	65
31 Mar 20	330	-126	226	58
31 Dec 19	302	-125	204	51
30 Sep 19	286	-121	189	49
30 Jun 19	273	-128	170	49
31 Mar 19	262	-129	161	48
31 Dec 18	258	-128	155	51
30 Sep 18	243	-144	163	50
30 Jun 18	233	-142	159	50
31 Mar 18	223	-137	156	50
31 Dec 17	210	-138	155	50
30 Sep 17	207	-128	144	49
30 Jun 17	205	-126	144	47
31 Mar 17	205	-121	143	46
31 Dec 16	213	-100	136	42
30 Sep 16	221	-81	129	38
30 Jun 16	212	-72	122	34
31 Mar 16	205	-69	117	31
31 Dec 15	190	-70	110	28
30 Sep 15	187	-46	98	24
30 Jun 15	189	-28	86	21
31 Mar 15	179	-6	72	19
31 Dec 14	159	-5	63	17
30 Sep 14	133	-11	55	16
31 Mar 14	78	-29	40	13
31 Dec 13	55	-37	32	12

Ingresos de calidad: NTRA actualmente no es rentable.

Margen de beneficios creciente: NTRA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: NTRA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 32% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de NTRA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: NTRA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: NTRA tiene una rentabilidad financiera negativa (-56.81%), ya que actualmente no es rentable.

Natera Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Natera, Inc., Annual General Meeting, Jun 12, 2024

CEO & Director notifies of intention to sell stock

Now 20% undervalued

Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation

Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 11%

Is Natera (NASDAQ:NTRA) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$86.94

Natera, Inc. Provides Earnings Guidance for the Year 2024

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Provides Update on Ravgen Trial

Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Natera, Inc. Raises Revenue Guidance for the Full Year 2023

Is Natera (NASDAQ:NTRA) A Risky Investment?

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Announces Updated Data from the Galaxy Arm of the Circulate-Japan Trial

Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Natera, Inc. to Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Natera, Inc. Announces New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Natera, Inc. Announces Senior Leadership Appointments

Natera, Inc. Announces Expanded I-Spy 2 Collaboration to Evaluate Signatera™? for Breast Cancer Patients in the Neoadjuvant Setting

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Co-Founder & Director notifies of intention to sell stock

Natera's Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. Revises Earnings Guidance for the Year 2023

Natera Announces Completion of Enrollment to the Randomized, Phase III Altair Trial of Signatera in Colorectal Cancer

Co-Founder & Director notifies of intention to sell stock

United States District Court for the District of Delaware Issues Favorable Ruling for Natera, Inc. in False Advertising Trial Against CareDx, Inc

Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 1000 Value Index

Natera, Inc. Announces Data from the ProActive Study that Supports Prospera™? Kidney as an Early Indicator of Transplant Rejection

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Natera, Inc. Raises Earnings Guidance for the Year 2023

Natera, Inc. Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

CEO, President & Director exercised options and sold US$140k worth of stock

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

CEO, President & Director exercised options and sold US$184k worth of stock

Consensus EPS estimates upgraded to US$4.08 loss

Chief Financial Officer exercised options and sold US$255k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Medicare Extends Coverage of Natera's Signatera(TM) MRD Test to Breast Cancer

Chief Financial Officer notifies of intention to sell stock

CEO, President & Director exercised options and sold US$223k worth of stock

Foundation Medicine, Inc. and Natera, Inc. Announce the Launch of FoundationOne Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use

CEO, President & Director exercised options and sold US$70k worth of stock

CEO, President & Director exercised options and sold US$72k worth of stock

Natera, Inc. Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

Desglose de ingresos y gastos
Beta